210 related articles for article (PubMed ID: 31127562)
1. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
2. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma.
Koomen DC; Meads MB; Magaletti DM; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meke LE; Jiang Z; Hampton OA; Tungesvik A; De Avila G; Alugubelli RR; Nishihori T; Silva AS; Eschrich SA; Garrett TJ; Koomen JM; Shain KH
J Proteome Res; 2021 Jun; 20(6):3134-3149. PubMed ID: 34014671
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC
Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
8. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
10. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
[TBL] [Abstract][Full Text] [Related]
11. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
12. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
14. Melphalan Flufenamide (Melflufen): First Approval.
Dhillon S
Drugs; 2021 Jun; 81(8):963-969. PubMed ID: 33961277
[TBL] [Abstract][Full Text] [Related]
15. Melflufen for relapsed and refractory multiple myeloma.
Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
[TBL] [Abstract][Full Text] [Related]
16. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
17. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Kaiser M; Lamottke B; Mieth M; Jensen MR; Quadt C; Garcia-Echeverria C; Atadja P; Heider U; von Metzler I; Türkmen S; Sezer O
Eur J Haematol; 2010 Apr; 84(4):337-44. PubMed ID: 20028416
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
19. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
20. Melphalan hydrochloride for the treatment of multiple myeloma.
Esma F; Salvini M; Troia R; Boccadoro M; Larocca A; Pautasso C
Expert Opin Pharmacother; 2017 Aug; 18(11):1127-1136. PubMed ID: 28658983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
